• AstraZeneca’s Tagrisso Nabs Another Lung Cancer Approval biospace
    April 20, 2018
    FDA approved AstraZeneca’s Tagrisso (osimertinib) for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) in tumors with epidermal growth factor receptor (EGFR) mutations.
PharmaSources Customer Service